Survival improvement for patients with metastatic colorectal cancer over twenty years

Over the past two decades of successive clinical trials in metastatic colorectal cancer (CRC), the median overall survival of both control and experimental arms has steadily improved. However, the incremental change in survival for metastatic CRC patients not treated on trial has not yet been quanti...

Full description

Saved in:
Bibliographic Details
Published inNPJ precision oncology Vol. 7; no. 1; pp. 16 - 9
Main Authors Zeineddine, Fadl A., Zeineddine, Mohammad A., Yousef, Abdelrahman, Gu, Yue, Chowdhury, Saikat, Dasari, Arvind, Huey, Ryan W., Johnson, Benny, Kee, Bryan, Lee, Michael S., Morelli, Maria Pia, Morris, Van K., Overman, Michael J., Parseghian, Christine, Raghav, Kanwal, Willis, Jason, Wolff, Robert A., Kawaguchi, Yoshikuni, Vauthey, Jean-Nicolas, Sun, Ryan, Kopetz, Scott, Shen, John Paul
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 13.02.2023
Nature Publishing Group
Nature Portfolio
Subjects
692/4028/67/1059/99
692/4028/67/1504/1885
692/53/2422
692/699/1503/1504/1885
Antiviral drugs
Cancer Research
Chemotherapy
Colorectal cancer
Gene Therapy
Human Genetics
Immunotherapy
Inhibitor drugs
Internal Medicine
Medicine
Medicine & Public Health
Metastasis
Oncology
Targeted cancer therapy
Online AccessGet full text

Cover

Abstract Over the past two decades of successive clinical trials in metastatic colorectal cancer (CRC), the median overall survival of both control and experimental arms has steadily improved. However, the incremental change in survival for metastatic CRC patients not treated on trial has not yet been quantified. We performed a retrospective review of 1420 patients with de novo metastatic CRC who received their primary treatment at the University of Texas M.D. Anderson Cancer Center (UTMDACC) from 2004 through 2019. Median OS was roughly stable for patients diagnosed between 2004 and 2012 (22.6 months) but since has steadily improved for those diagnosed in 2013 to 2015 (28.8 months), and 2016 to 2019 (32.4 months). Likewise, 5-year survival rate has increased from 15.7% for patients diagnosed from 2004 to 2006 to 26% for those diagnosed from 2013 to 2015. Notably, survival improved for patients with BRAF V600E mutant as well as microsatellite unstable (MSI-H) tumors. Multivariate regression analysis identified surgical resection of liver metastasis (HR = 0.26, 95% CI, 0.19–0.37), use of immunotherapy (HR = 0.44, 95% CI, 0.29–0.67) and use of third line chemotherapy (regorafenib or trifluridine/tipiracil, HR = 0.74, 95% CI, 0.58–0.95), but not year of diagnosis (HR = 0.99, 95% CI, 0.98–1), as associated with better survival, suggesting that increased use of these therapies are the drivers of the observed improvement in survival.
AbstractList Over the past two decades of successive clinical trials in metastatic colorectal cancer (CRC), the median overall survival of both control and experimental arms has steadily improved. However, the incremental change in survival for metastatic CRC patients not treated on trial has not yet been quantified. We performed a retrospective review of 1420 patients with de novo metastatic CRC who received their primary treatment at the University of Texas M.D. Anderson Cancer Center (UTMDACC) from 2004 through 2019. Median OS was roughly stable for patients diagnosed between 2004 and 2012 (22.6 months) but since has steadily improved for those diagnosed in 2013 to 2015 (28.8 months), and 2016 to 2019 (32.4 months). Likewise, 5-year survival rate has increased from 15.7% for patients diagnosed from 2004 to 2006 to 26% for those diagnosed from 2013 to 2015. Notably, survival improved for patients with BRAF V600E mutant as well as microsatellite unstable (MSI-H) tumors. Multivariate regression analysis identified surgical resection of liver metastasis (HR = 0.26, 95% CI, 0.19–0.37), use of immunotherapy (HR = 0.44, 95% CI, 0.29–0.67) and use of third line chemotherapy (regorafenib or trifluridine/tipiracil, HR = 0.74, 95% CI, 0.58–0.95), but not year of diagnosis (HR = 0.99, 95% CI, 0.98–1), as associated with better survival, suggesting that increased use of these therapies are the drivers of the observed improvement in survival.
Over the past two decades of successive clinical trials in metastatic colorectal cancer (CRC), the median overall survival of both control and experimental arms has steadily improved. However, the incremental change in survival for metastatic CRC patients not treated on trial has not yet been quantified. We performed a retrospective review of 1420 patients with de novo metastatic CRC who received their primary treatment at the University of Texas M.D. Anderson Cancer Center (UTMDACC) from 2004 through 2019. Median OS was roughly stable for patients diagnosed between 2004 and 2012 (22.6 months) but since has steadily improved for those diagnosed in 2013 to 2015 (28.8 months), and 2016 to 2019 (32.4 months). Likewise, 5-year survival rate has increased from 15.7% for patients diagnosed from 2004 to 2006 to 26% for those diagnosed from 2013 to 2015. Notably, survival improved for patients with BRAFV600E mutant as well as microsatellite unstable (MSI-H) tumors. Multivariate regression analysis identified surgical resection of liver metastasis (HR = 0.26, 95% CI, 0.19–0.37), use of immunotherapy (HR = 0.44, 95% CI, 0.29–0.67) and use of third line chemotherapy (regorafenib or trifluridine/tipiracil, HR = 0.74, 95% CI, 0.58–0.95), but not year of diagnosis (HR = 0.99, 95% CI, 0.98–1), as associated with better survival, suggesting that increased use of these therapies are the drivers of the observed improvement in survival.
Over the past two decades of successive clinical trials in metastatic colorectal cancer (CRC), the median overall survival of both control and experimental arms has steadily improved. However, the incremental change in survival for metastatic CRC patients not treated on trial has not yet been quantified. We performed a retrospective review of 1420 patients with de novo metastatic CRC who received their primary treatment at the University of Texas M.D. Anderson Cancer Center (UTMDACC) from 2004 through 2019. Median OS was roughly stable for patients diagnosed between 2004 and 2012 (22.6 months) but since has steadily improved for those diagnosed in 2013 to 2015 (28.8 months), and 2016 to 2019 (32.4 months). Likewise, 5-year survival rate has increased from 15.7% for patients diagnosed from 2004 to 2006 to 26% for those diagnosed from 2013 to 2015. Notably, survival improved for patients with BRAFV600E mutant as well as microsatellite unstable (MSI-H) tumors. Multivariate regression analysis identified surgical resection of liver metastasis (HR = 0.26, 95% CI, 0.19-0.37), use of immunotherapy (HR = 0.44, 95% CI, 0.29-0.67) and use of third line chemotherapy (regorafenib or trifluridine/tipiracil, HR = 0.74, 95% CI, 0.58-0.95), but not year of diagnosis (HR = 0.99, 95% CI, 0.98-1), as associated with better survival, suggesting that increased use of these therapies are the drivers of the observed improvement in survival.Over the past two decades of successive clinical trials in metastatic colorectal cancer (CRC), the median overall survival of both control and experimental arms has steadily improved. However, the incremental change in survival for metastatic CRC patients not treated on trial has not yet been quantified. We performed a retrospective review of 1420 patients with de novo metastatic CRC who received their primary treatment at the University of Texas M.D. Anderson Cancer Center (UTMDACC) from 2004 through 2019. Median OS was roughly stable for patients diagnosed between 2004 and 2012 (22.6 months) but since has steadily improved for those diagnosed in 2013 to 2015 (28.8 months), and 2016 to 2019 (32.4 months). Likewise, 5-year survival rate has increased from 15.7% for patients diagnosed from 2004 to 2006 to 26% for those diagnosed from 2013 to 2015. Notably, survival improved for patients with BRAFV600E mutant as well as microsatellite unstable (MSI-H) tumors. Multivariate regression analysis identified surgical resection of liver metastasis (HR = 0.26, 95% CI, 0.19-0.37), use of immunotherapy (HR = 0.44, 95% CI, 0.29-0.67) and use of third line chemotherapy (regorafenib or trifluridine/tipiracil, HR = 0.74, 95% CI, 0.58-0.95), but not year of diagnosis (HR = 0.99, 95% CI, 0.98-1), as associated with better survival, suggesting that increased use of these therapies are the drivers of the observed improvement in survival.
Abstract Over the past two decades of successive clinical trials in metastatic colorectal cancer (CRC), the median overall survival of both control and experimental arms has steadily improved. However, the incremental change in survival for metastatic CRC patients not treated on trial has not yet been quantified. We performed a retrospective review of 1420 patients with de novo metastatic CRC who received their primary treatment at the University of Texas M.D. Anderson Cancer Center (UTMDACC) from 2004 through 2019. Median OS was roughly stable for patients diagnosed between 2004 and 2012 (22.6 months) but since has steadily improved for those diagnosed in 2013 to 2015 (28.8 months), and 2016 to 2019 (32.4 months). Likewise, 5-year survival rate has increased from 15.7% for patients diagnosed from 2004 to 2006 to 26% for those diagnosed from 2013 to 2015. Notably, survival improved for patients with BRAF V600E mutant as well as microsatellite unstable (MSI-H) tumors. Multivariate regression analysis identified surgical resection of liver metastasis (HR = 0.26, 95% CI, 0.19–0.37), use of immunotherapy (HR = 0.44, 95% CI, 0.29–0.67) and use of third line chemotherapy (regorafenib or trifluridine/tipiracil, HR = 0.74, 95% CI, 0.58–0.95), but not year of diagnosis (HR = 0.99, 95% CI, 0.98–1), as associated with better survival, suggesting that increased use of these therapies are the drivers of the observed improvement in survival.
Over the past two decades of successive clinical trials in metastatic colorectal cancer (CRC), the median overall survival of both control and experimental arms has steadily improved. However, the incremental change in survival for metastatic CRC patients not treated on trial has not yet been quantified. We performed a retrospective review of 1420 patients with de novo metastatic CRC who received their primary treatment at the University of Texas M.D. Anderson Cancer Center (UTMDACC) from 2004 through 2019. Median OS was roughly stable for patients diagnosed between 2004 and 2012 (22.6 months) but since has steadily improved for those diagnosed in 2013 to 2015 (28.8 months), and 2016 to 2019 (32.4 months). Likewise, 5-year survival rate has increased from 15.7% for patients diagnosed from 2004 to 2006 to 26% for those diagnosed from 2013 to 2015. Notably, survival improved for patients with BRAF mutant as well as microsatellite unstable (MSI-H) tumors. Multivariate regression analysis identified surgical resection of liver metastasis (HR = 0.26, 95% CI, 0.19-0.37), use of immunotherapy (HR = 0.44, 95% CI, 0.29-0.67) and use of third line chemotherapy (regorafenib or trifluridine/tipiracil, HR = 0.74, 95% CI, 0.58-0.95), but not year of diagnosis (HR = 0.99, 95% CI, 0.98-1), as associated with better survival, suggesting that increased use of these therapies are the drivers of the observed improvement in survival.
ArticleNumber 16
Author Parseghian, Christine
Yousef, Abdelrahman
Chowdhury, Saikat
Wolff, Robert A.
Huey, Ryan W.
Kee, Bryan
Vauthey, Jean-Nicolas
Zeineddine, Fadl A.
Willis, Jason
Overman, Michael J.
Raghav, Kanwal
Sun, Ryan
Lee, Michael S.
Morelli, Maria Pia
Gu, Yue
Shen, John Paul
Morris, Van K.
Kawaguchi, Yoshikuni
Zeineddine, Mohammad A.
Kopetz, Scott
Dasari, Arvind
Johnson, Benny
Author_xml – sequence: 1
  givenname: Fadl A.
  surname: Zeineddine
  fullname: Zeineddine, Fadl A.
  organization: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
– sequence: 2
  givenname: Mohammad A.
  orcidid: 0000-0001-8075-765X
  surname: Zeineddine
  fullname: Zeineddine, Mohammad A.
  organization: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
– sequence: 3
  givenname: Abdelrahman
  orcidid: 0000-0001-7761-8149
  surname: Yousef
  fullname: Yousef, Abdelrahman
  organization: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
– sequence: 4
  givenname: Yue
  orcidid: 0000-0002-9642-0338
  surname: Gu
  fullname: Gu, Yue
  organization: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
– sequence: 5
  givenname: Saikat
  orcidid: 0000-0002-0783-3959
  surname: Chowdhury
  fullname: Chowdhury, Saikat
  organization: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
– sequence: 6
  givenname: Arvind
  surname: Dasari
  fullname: Dasari, Arvind
  organization: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
– sequence: 7
  givenname: Ryan W.
  orcidid: 0000-0002-7887-8484
  surname: Huey
  fullname: Huey, Ryan W.
  organization: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
– sequence: 8
  givenname: Benny
  surname: Johnson
  fullname: Johnson, Benny
  organization: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
– sequence: 9
  givenname: Bryan
  surname: Kee
  fullname: Kee, Bryan
  organization: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
– sequence: 10
  givenname: Michael S.
  surname: Lee
  fullname: Lee, Michael S.
  organization: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
– sequence: 11
  givenname: Maria Pia
  surname: Morelli
  fullname: Morelli, Maria Pia
  organization: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
– sequence: 12
  givenname: Van K.
  surname: Morris
  fullname: Morris, Van K.
  organization: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
– sequence: 13
  givenname: Michael J.
  surname: Overman
  fullname: Overman, Michael J.
  organization: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
– sequence: 14
  givenname: Christine
  surname: Parseghian
  fullname: Parseghian, Christine
  organization: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
– sequence: 15
  givenname: Kanwal
  orcidid: 0000-0003-1311-4173
  surname: Raghav
  fullname: Raghav, Kanwal
  organization: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
– sequence: 16
  givenname: Jason
  orcidid: 0000-0001-8238-8552
  surname: Willis
  fullname: Willis, Jason
  organization: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
– sequence: 17
  givenname: Robert A.
  surname: Wolff
  fullname: Wolff, Robert A.
  organization: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
– sequence: 18
  givenname: Yoshikuni
  orcidid: 0000-0003-2986-3224
  surname: Kawaguchi
  fullname: Kawaguchi, Yoshikuni
  organization: Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center
– sequence: 19
  givenname: Jean-Nicolas
  surname: Vauthey
  fullname: Vauthey, Jean-Nicolas
  organization: Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center
– sequence: 20
  givenname: Ryan
  surname: Sun
  fullname: Sun, Ryan
  organization: Department of Biostatistics, The University of Texas MD Anderson Cancer Center
– sequence: 21
  givenname: Scott
  surname: Kopetz
  fullname: Kopetz, Scott
  organization: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
– sequence: 22
  givenname: John Paul
  orcidid: 0000-0003-4588-2775
  surname: Shen
  fullname: Shen, John Paul
  email: Jshen8@mdanderson.org
  organization: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36781990$$D View this record in MEDLINE/PubMed
BookMark eNp9Uk1v1DAUtFARLUv_AAcUiQuXgD9j-4KEqgKVKnGAStws23nZepXEi51stf8ep9tC20NPfnpvZjz2m9foaIwjIPSW4I8EM_Upc9JoVWPKaoyZYDV_gU4o07KWjfp99KA-Rqc5bzDGRAlCm-YVOmaNVERrfIKufs5pF3a2r8KwTXEHA4xT1cVUbe0USp2rmzBdVwNMNk-l5Ssf-5jAT4Xj7eghVYWWqummoPfVHmzKb9DLzvYZTu_OFbr6ev7r7Ht9-ePbxdmXy9oLjqdaO6KJdIIxz2wLxAF1zOPOYS7AO2gw6YSyhDsgQgAVLYDtmFUtLmPfshW6OOi20W7MNoXBpr2JNpjbRkxrY1Px3IORTnecSee5kJwQ5jrMLcO0k43AVIii9fmgtZ3dAK0vr0m2fyT6eDKGa7OOO6M1LZKLwIc7gRT_zJAnM4Tsoe_tCHHOhspyFRFM0wJ9_wS6iXMay1ctKKGkosXiCr176OiflfvtFYA6AHyKOSfojA_LjuJiMPSGYLNkxRyyYkpWzG1WDC9U-oR6r_4siR1IuYDHNaT_tp9h_QUvIdL-
CitedBy_id crossref_primary_10_1016_j_cireng_2023_11_025
crossref_primary_10_1016_j_apsb_2024_03_020
crossref_primary_10_3390_cancers16223870
crossref_primary_10_1186_s12935_023_03135_x
crossref_primary_10_1245_s10434_024_16488_y
crossref_primary_10_1080_0284186X_2023_2259083
crossref_primary_10_5306_wjco_v16_i3_102076
crossref_primary_10_7759_cureus_45641
crossref_primary_10_1038_s41597_024_04323_8
crossref_primary_10_4251_wjgo_v17_i4_103029
crossref_primary_10_1002_cam4_70530
crossref_primary_10_1002_ptr_8303
crossref_primary_10_3390_cancers16081460
crossref_primary_10_3831_KPI_2024_27_4_332
crossref_primary_10_1097_JS9_0000000000001811
crossref_primary_10_1080_00365521_2024_2411405
crossref_primary_10_3390_life14081008
crossref_primary_10_1016_j_soi_2024_100076
crossref_primary_10_3892_ol_2025_14979
crossref_primary_10_1016_j_ejso_2025_109718
crossref_primary_10_1007_s00259_024_06731_9
crossref_primary_10_1186_s40959_024_00299_x
crossref_primary_10_3389_fonc_2023_1272561
crossref_primary_10_1007_s12672_024_01321_5
crossref_primary_10_1002_jso_27944
crossref_primary_10_3390_cancers16091645
crossref_primary_10_1080_14796694_2024_2441101
crossref_primary_10_1016_j_ciresp_2023_11_012
crossref_primary_10_3390_cancers16051029
crossref_primary_10_1038_s41698_024_00505_0
crossref_primary_10_1016_j_ejso_2024_108057
crossref_primary_10_1007_s11864_024_01186_4
crossref_primary_10_3390_cancers16071360
crossref_primary_10_1111_ajco_14132
crossref_primary_10_1016_j_clcc_2024_10_001
crossref_primary_10_1016_j_ctrv_2024_102700
crossref_primary_10_1016_j_clcc_2024_01_004
crossref_primary_10_1001_jamaoncol_2024_3666
crossref_primary_10_1016_j_gassur_2025_101954
crossref_primary_10_1093_oncolo_oyae367
crossref_primary_10_1200_OA_24_00071
crossref_primary_10_1002_ijc_35285
crossref_primary_10_1007_s12029_025_01166_3
crossref_primary_10_1016_S1470_2045_23_00614_9
crossref_primary_10_20517_evcna_2024_43
crossref_primary_10_1038_s41598_024_77248_2
crossref_primary_10_3390_cancers16010205
crossref_primary_10_3390_cancers17060969
crossref_primary_10_21303_2504_5679_2023_002881
crossref_primary_10_1001_jamanetworkopen_2024_0260
crossref_primary_10_3390_cancers16112004
crossref_primary_10_1245_s10434_023_14049_3
crossref_primary_10_1158_1541_7786_MCR_23_0468
crossref_primary_10_1245_s10434_024_16370_x
crossref_primary_10_1007_s40259_023_00624_3
crossref_primary_10_32322_jhsm_1341618
crossref_primary_10_1016_j_ejso_2024_108306
crossref_primary_10_1038_s41416_024_02826_0
crossref_primary_10_1093_oncolo_oyae114
crossref_primary_10_3390_curroncol31120571
crossref_primary_10_1371_journal_pone_0318834
crossref_primary_10_3390_nutraceuticals4040027
crossref_primary_10_1038_s41598_023_31538_3
crossref_primary_10_1016_j_hpb_2024_12_023
crossref_primary_10_1093_bjsopen_zrae054
crossref_primary_10_23736_S2724_5691_24_10363_2
crossref_primary_10_1080_14737140_2024_2447360
crossref_primary_10_3390_diagnostics13182930
Cites_doi 10.1158/1078-0432.CCR-19-0863
10.1126/science.aan6733
10.1093/annonc/mdn735
10.1093/annonc/mdi246
10.1016/j.ajpath.2017.07.023
10.1016/j.jmoldx.2016.09.011
10.1200/JCO.2004.10.012
10.1097/SLA.0000000000004331
10.1007/s11605-021-05110-1
10.1200/jco.2014.32.15_suppl.3515
10.1002/cam4.3316
10.1200/JCO.2015.63.2471
10.1056/NEJMoa2017699
10.1001/jama.2017.7105
10.1097/01.sla.0000128305.90650.71
10.1097/00000658-199610000-00009
10.1136/gut.2006.098053
10.1097/SLA.0000000000004672
10.1093/jnci/djh034
10.1016/0003-4975(92)91435-C
10.1046/j.0007-1323.2001.01821.x
10.1126/science.1133427
10.3390/cancers12061571
10.1016/S1470-2045(19)30862-9
10.1053/j.seminoncol.2007.01.003
10.1016/S1470-2045(17)30422-9
10.1038/nrm1907
10.1093/annonc/mdj007
10.1016/j.gendis.2019.10.013
10.1111/j.1477-2574.2012.00557.x
10.1097/01.sla.0000160703.75808.7d
10.1186/1471-2407-14-810
10.1200/JCO.19.02107
10.1016/S0140-6736(94)92529-1
10.1158/2159-8290.CD-14-0462
10.1200/JCO.2008.20.5278
10.6004/jnccn.2020.7596
10.1016/j.jamcollsurg.2021.05.027
10.1056/NEJMoa1908075
10.1001/archsurg.136.8.864
10.1245/s10434-021-10030-0
10.1093/annonc/mdw235
10.1016/j.crad.2021.06.005
10.1016/j.jval.2013.03.284
10.1007/s11605-021-05173-0
10.1056/NEJMoa1500596
10.1200/JCO.2007.11.0833
10.1097/SLA.0000000000002450
10.1097/00000658-200206000-00002
10.1038/nature00766
10.1200/JCO.1983.1.11.710
10.1016/j.ctrv.2015.06.006
10.1111/j.1467-985X.2004.00293.x
10.1111/j.1463-1318.2010.02539.x
10.1200/JCO.2017.76.9901
10.1016/j.jamcollsurg.2019.04.027
10.1093/bjs/znab086
ContentType Journal Article
Copyright The Author(s) 2023
2023. The Author(s).
The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2023
– notice: 2023. The Author(s).
– notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
NPM
3V.
7RV
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
KB0
M0S
NAPCQ
PHGZM
PHGZT
PIMPY
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1038/s41698-023-00353-4
DatabaseName Springer Nature OA Free Journals
CrossRef
PubMed
ProQuest Central (Corporate)
Nursing & Allied Health Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Health & Medical Collection
ProQuest Nursing and Allied Health Premium
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
CrossRef
Publicly Available Content Database
MEDLINE - Academic

PubMed
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2397-768X
EndPage 9
ExternalDocumentID oai_doaj_org_article_7b9f437bc4574113bf04a302f7650255
PMC9925745
36781990
10_1038_s41698_023_00353_4
Genre Journal Article
GrantInformation_xml – fundername: U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
  grantid: SPORE P50CA221707
  funderid: https://doi.org/10.13039/100000054
– fundername: Cancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas)
  funderid: https://doi.org/10.13039/100004917
– fundername: NCI NIH HHS
  grantid: P50 CA221707
– fundername: ;
– fundername: ;
  grantid: SPORE P50CA221707
GroupedDBID 0R~
53G
7RV
7X7
8FI
8FJ
AAJSJ
AAKAB
ABUWG
ACGFS
ACSMW
ADBBV
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BCNDV
BENPR
C6C
CCPQU
EBLON
EBS
EMOBN
FYUFA
GROUPED_DOAJ
HMCUK
HYE
M~E
NAO
NAPCQ
NO~
OK1
PGMZT
PIMPY
RNT
RPM
SNYQT
UKHRP
AASML
AAYXX
CITATION
PHGZM
PHGZT
NPM
PPXIY
3V.
7XB
8FK
AARCD
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c540t-9b1917b533c3ade1be2b3c0fb045ecbe601f58a14be155e25deeaf3a8d0ecbcd3
IEDL.DBID DOA
ISSN 2397-768X
IngestDate Wed Aug 27 01:27:53 EDT 2025
Thu Aug 21 18:38:08 EDT 2025
Fri Jul 11 02:22:59 EDT 2025
Wed Aug 13 10:48:06 EDT 2025
Mon Jul 21 05:25:28 EDT 2025
Tue Jul 01 00:35:45 EDT 2025
Thu Apr 24 23:08:40 EDT 2025
Fri Feb 21 02:39:58 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2023. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c540t-9b1917b533c3ade1be2b3c0fb045ecbe601f58a14be155e25deeaf3a8d0ecbcd3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-8238-8552
0000-0002-0783-3959
0000-0001-8075-765X
0000-0002-9642-0338
0000-0003-1311-4173
0000-0001-7761-8149
0000-0002-7887-8484
0000-0003-2986-3224
0000-0003-4588-2775
OpenAccessLink https://doaj.org/article/7b9f437bc4574113bf04a302f7650255
PMID 36781990
PQID 2775878211
PQPubID 4669714
PageCount 9
ParticipantIDs doaj_primary_oai_doaj_org_article_7b9f437bc4574113bf04a302f7650255
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9925745
proquest_miscellaneous_2776515392
proquest_journals_2775878211
pubmed_primary_36781990
crossref_citationtrail_10_1038_s41698_023_00353_4
crossref_primary_10_1038_s41698_023_00353_4
springer_journals_10_1038_s41698_023_00353_4
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-02-13
PublicationDateYYYYMMDD 2023-02-13
PublicationDate_xml – month: 02
  year: 2023
  text: 2023-02-13
  day: 13
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle NPJ precision oncology
PublicationTitleAbbrev npj Precis. Onc
PublicationTitleAlternate NPJ Precis Oncol
PublicationYear 2023
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Luthra (CR64) 2017; 19
Singh, Rai, Pandey, Singh, Srivastava (CR1) 2021; 8
Abdalla (CR22) 2004; 239
Nordlinger (CR36) 2009; 20
Kawaguchi (CR49) 2021; 108
Adam (CR53) 2015; 41
McAfee (CR59) 1992; 53
Kopetz (CR11) 2019; 381
CR39
Corcoran (CR9) 2015; 33
Tomlinson (CR21) 2007; 25
Kopetz (CR4) 2009; 27
Van Cutsem (CR5) 2016; 27
Lillemoe (CR31) 2022; 276
Adam (CR45) 2007; 34
Loeb, Springgate, Battula (CR12) 1974; 34
Overman (CR18) 2017; 18
Kawaguchi (CR46) 2019; 229
Ignatavicius (CR50) 2020; 272
Adams (CR27) 2013; 15
CR3
Kawaguchi (CR28) 2020; 18
Kawaguchi (CR29) 2021; 233
Bismuth (CR33) 1996; 224
Nishioka (CR48) 2022; 26
Kawaguchi (CR23) 2022; 26
Chun (CR47) 2019; 269
Davies (CR6) 2002; 417
Pawlik (CR44) 2005; 241
Umar (CR65) 2004; 96
Bendell (CR10) 2014; 32
Figueras (CR42) 2001; 88
Choti (CR41) 2002; 235
Molina-Cerrillo (CR8) 2020; 12
Cremolini (CR37) 2020; 21
van der Pool (CR24) 2012; 14
Goiffon, O’Shea, Harisinghani (CR54) 2021; 76
Burzykowski, Buyse (CR63) 2004; 167
André (CR15) 2020; 383
Kanas (CR26) 2012; 4
Anderson, Cain, Gelber (CR62) 1983; 1
Farr, Foley (CR40) 2013; 16
Le (CR16) 2015; 372
Sjöblom (CR2) 2006; 314
Abdalla (CR43) 2004; 239
Woods, Rachet, Coleman (CR56) 2006; 17
Augustus, Ellis (CR57) 2018; 188
Jiricny (CR13) 2006; 7
Le (CR17) 2017; 357
Glehen (CR58) 2004; 22
Kawaguchi (CR30) 2019; 25
Le (CR19) 2020; 38
Garden (CR34) 2006; 55
Bowles (CR52) 2001; 136
Vega (CR60) 2021; 28
Battaglin, Naseem, Lenz, Salem (CR14) 2018; 16
Wilkes (CR25) 2011; 25
Raoof (CR61) 2020; 9
Venook (CR38) 2017; 317
Overman (CR20) 2018; 36
Stangl, Altendorf-Hofmann, Charnley, Scheele (CR35) 1994; 343
Misale, Di Nicolantonio, Sartore-Bianchi, Siena, Bardelli (CR55) 2014; 4
Folprecht, Grothey, Alberts, Raab, Kohne (CR32) 2005; 16
Hackl (CR51) 2014; 14
Clarke, Kopetz (CR7) 2015; 6
LM Woods (353_CR56) 2006; 17
RB Adams (353_CR27) 2013; 15
R Adam (353_CR53) 2015; 41
S Kopetz (353_CR11) 2019; 381
J Jiricny (353_CR13) 2006; 7
M Raoof (353_CR61) 2020; 9
JS Tomlinson (353_CR21) 2007; 25
DT Le (353_CR19) 2020; 38
Y Nishioka (353_CR48) 2022; 26
T Sjöblom (353_CR2) 2006; 314
C Hackl (353_CR51) 2014; 14
R Adam (353_CR45) 2007; 34
EA Vega (353_CR60) 2021; 28
JC Bendell (353_CR10) 2014; 32
G Folprecht (353_CR32) 2005; 16
C Cremolini (353_CR37) 2020; 21
S Misale (353_CR55) 2014; 4
B Nordlinger (353_CR36) 2009; 20
BJ Bowles (353_CR52) 2001; 136
A Umar (353_CR65) 2004; 96
TM Pawlik (353_CR44) 2005; 241
EK Abdalla (353_CR22) 2004; 239
O Glehen (353_CR58) 2004; 22
GP Kanas (353_CR26) 2012; 4
TMG Burzykowski (353_CR63) 2004; 167
YS Chun (353_CR47) 2019; 269
RB Corcoran (353_CR9) 2015; 33
T André (353_CR15) 2020; 383
Y Kawaguchi (353_CR46) 2019; 229
J Molina-Cerrillo (353_CR8) 2020; 12
MP Singh (353_CR1) 2021; 8
AM Farr (353_CR40) 2013; 16
H Davies (353_CR6) 2002; 417
MJ Overman (353_CR18) 2017; 18
EK Abdalla (353_CR43) 2004; 239
P Ignatavicius (353_CR50) 2020; 272
S Kopetz (353_CR4) 2009; 27
353_CR3
Y Kawaguchi (353_CR30) 2019; 25
R Stangl (353_CR35) 1994; 343
LA Loeb (353_CR12) 1974; 34
AE van der Pool (353_CR24) 2012; 14
MA Choti (353_CR41) 2002; 235
GM Wilkes (353_CR25) 2011; 25
GJ Augustus (353_CR57) 2018; 188
HA Lillemoe (353_CR31) 2022; 276
RJ Goiffon (353_CR54) 2021; 76
MJ Overman (353_CR20) 2018; 36
AP Venook (353_CR38) 2017; 317
353_CR39
R Luthra (353_CR64) 2017; 19
Y Kawaguchi (353_CR49) 2021; 108
J Figueras (353_CR42) 2001; 88
MK McAfee (353_CR59) 1992; 53
JR Anderson (353_CR62) 1983; 1
Y Kawaguchi (353_CR23) 2022; 26
OJ Garden (353_CR34) 2006; 55
Y Kawaguchi (353_CR28) 2020; 18
F Battaglin (353_CR14) 2018; 16
Y Kawaguchi (353_CR29) 2021; 233
CN Clarke (353_CR7) 2015; 6
DT Le (353_CR16) 2015; 372
DT Le (353_CR17) 2017; 357
E Van Cutsem (353_CR5) 2016; 27
H Bismuth (353_CR33) 1996; 224
References_xml – volume: 25
  start-page: 5843
  year: 2019
  end-page: 5851
  ident: CR30
  article-title: Mutation status of RAS, TP53, and SMAD4 is superior to mutation status of RAS alone for predicting prognosis after resection of colorectal liver metastases
  publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.
  doi: 10.1158/1078-0432.CCR-19-0863
– volume: 357
  start-page: 409
  year: 2017
  end-page: 413
  ident: CR17
  article-title: Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
  publication-title: Science
  doi: 10.1126/science.aan6733
– volume: 20
  start-page: 985
  year: 2009
  end-page: 992
  ident: CR36
  article-title: Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdn735
– volume: 16
  start-page: 1311
  year: 2005
  end-page: 1319
  ident: CR32
  article-title: Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdi246
– ident: CR39
– volume: 6
  start-page: 660
  year: 2015
  end-page: 667
  ident: CR7
  article-title: BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies
  publication-title: J. Gastrointest. Oncol.
– volume: 188
  start-page: 291
  year: 2018
  end-page: 303
  ident: CR57
  article-title: Colorectal cancer disparity in african americans: risk factors and carcinogenic mechanisms
  publication-title: Am. J. Pathol.
  doi: 10.1016/j.ajpath.2017.07.023
– volume: 19
  start-page: 255
  year: 2017
  end-page: 264
  ident: CR64
  article-title: A targeted high-throughput next-generation sequencing panel for clinical screening of mutations, gene amplifications, and fusions in solid tumors
  publication-title: J. Mol. Diagn.
  doi: 10.1016/j.jmoldx.2016.09.011
– volume: 22
  start-page: 3284
  year: 2004
  end-page: 3292
  ident: CR58
  article-title: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2004.10.012
– volume: 272
  start-page: 715
  year: 2020
  end-page: 722
  ident: CR50
  article-title: Choices of therapeutic strategies for colorectal liver metastases among expert liver surgeons: a throw of the dice?
  publication-title: Ann. Surg.
  doi: 10.1097/SLA.0000000000004331
– volume: 26
  start-page: 583
  year: 2022
  end-page: 593
  ident: CR23
  article-title: Improved survival over time after resection of colorectal liver metastases and clinical impact of multigene alteration testing in patients with metastatic colorectal cancer
  publication-title: J. Gastrointest. Surg.
  doi: 10.1007/s11605-021-05110-1
– volume: 32
  start-page: 3515
  year: 2014
  end-page: 3515
  ident: CR10
  article-title: Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC)
  publication-title: J. Clin. Oncol.
  doi: 10.1200/jco.2014.32.15_suppl.3515
– volume: 9
  start-page: 6256
  year: 2020
  end-page: 6267
  ident: CR61
  article-title: Systematic failure to operate on colorectal cancer liver metastases in California
  publication-title: Cancer. Med.
  doi: 10.1002/cam4.3316
– volume: 33
  start-page: 4023
  year: 2015
  end-page: 4031
  ident: CR9
  article-title: Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2015.63.2471
– volume: 383
  start-page: 2207
  year: 2020
  end-page: 2218
  ident: CR15
  article-title: Pembrolizumab in microsatellite-instability–high advanced colorectal cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2017699
– volume: 317
  start-page: 2392
  year: 2017
  end-page: 2401
  ident: CR38
  article-title: Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients With KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial
  publication-title: JAMA
  doi: 10.1001/jama.2017.7105
– volume: 239
  start-page: 818
  year: 2004
  end-page: 827
  ident: CR22
  article-title: Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases
  publication-title: Ann. Surg.
  doi: 10.1097/01.sla.0000128305.90650.71
– volume: 224
  start-page: 509
  year: 1996
  end-page: 520
  ident: CR33
  article-title: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy
  publication-title: Ann. Surg.
  doi: 10.1097/00000658-199610000-00009
– volume: 55
  start-page: iii1
  year: 2006
  end-page: iii8
  ident: CR34
  article-title: Guidelines for resection of colorectal cancer liver metastases
  publication-title: Gut
  doi: 10.1136/gut.2006.098053
– volume: 34
  start-page: 2311
  year: 1974
  end-page: 2321
  ident: CR12
  article-title: Errors in DNA replication as a basis of malignant changes
  publication-title: Cancer. Res
– volume: 276
  start-page: 357
  year: 2022
  end-page: 362
  ident: CR31
  article-title: RAS/TP53 co-Mutation is Associated with Worse Survival after Concurrent Resection of Colorectal Liver Metastases and Extrahepatic Disease
  publication-title: Ann. Surg.
  doi: 10.1097/SLA.0000000000004672
– volume: 96
  start-page: 261
  year: 2004
  end-page: 268
  ident: CR65
  article-title: Revised bethesda guidelines for hereditary nonpolyposis colorectal cancer (lynch syndrome) and microsatellite instability
  publication-title: JNCI: J. Natl. Cancer Inst.
  doi: 10.1093/jnci/djh034
– volume: 25
  start-page: 32
  year: 2011
  end-page: 44
  ident: CR25
  article-title: Metastatic colorectal cancer: management challenges and opportunities
  publication-title: Oncol. (Williston Park)
– volume: 53
  start-page: 780
  year: 1992
  end-page: 785
  ident: CR59
  article-title: Colorectal lung metastases: results of surgical excision
  publication-title: Ann. Thorac. Surg.
  doi: 10.1016/0003-4975(92)91435-C
– volume: 88
  start-page: 980
  year: 2001
  end-page: 985
  ident: CR42
  article-title: Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases
  publication-title: Br. J. Surg.
  doi: 10.1046/j.0007-1323.2001.01821.x
– volume: 314
  start-page: 268
  year: 2006
  end-page: 274
  ident: CR2
  article-title: The consensus coding sequences of human breast and colorectal cancers
  publication-title: Science
  doi: 10.1126/science.1133427
– volume: 12
  start-page: 1571
  year: 2020
  ident: CR8
  article-title: BRAF mutated colorectal cancer: new treatment approaches
  publication-title: Cancers
  doi: 10.3390/cancers12061571
– volume: 21
  start-page: 497
  year: 2020
  end-page: 507
  ident: CR37
  article-title: Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(19)30862-9
– volume: 34
  start-page: S7
  year: 2007
  end-page: S11
  ident: CR45
  article-title: Developing strategies for liver metastases from colorectal cancer
  publication-title: Semin Oncol.
  doi: 10.1053/j.seminoncol.2007.01.003
– volume: 18
  start-page: 1182
  year: 2017
  end-page: 1191
  ident: CR18
  article-title: Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(17)30422-9
– volume: 7
  start-page: 335
  year: 2006
  end-page: 346
  ident: CR13
  article-title: The multifaceted mismatch-repair system
  publication-title: Nat. Rev. Mol. Cell Biol.
  doi: 10.1038/nrm1907
– volume: 17
  start-page: 5
  year: 2006
  end-page: 19
  ident: CR56
  article-title: Origins of socio-economic inequalities in cancer survival: a review
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdj007
– volume: 8
  start-page: 133
  year: 2021
  end-page: 145
  ident: CR1
  article-title: Molecular subtypes of colorectal cancer: an emerging therapeutic opportunity for personalized medicine
  publication-title: Genes Dis.
  doi: 10.1016/j.gendis.2019.10.013
– volume: 15
  start-page: 91
  year: 2013
  end-page: 103
  ident: CR27
  article-title: Selection for hepatic resection of colorectal liver metastases: expert consensus statement
  publication-title: HPB
  doi: 10.1111/j.1477-2574.2012.00557.x
– volume: 241
  start-page: 715
  year: 2005
  end-page: 722
  ident: CR44
  article-title: Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases
  publication-title: Ann. Surg.
  doi: 10.1097/01.sla.0000160703.75808.7d
– volume: 14
  year: 2014
  ident: CR51
  article-title: Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-14-810
– volume: 4
  start-page: 283
  year: 2012
  end-page: 301
  ident: CR26
  article-title: Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors
  publication-title: Clin. Epidemiol.
– volume: 38
  start-page: 11
  year: 2020
  end-page: 19
  ident: CR19
  article-title: Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.19.02107
– volume: 343
  start-page: 1405
  year: 1994
  end-page: 1410
  ident: CR35
  article-title: Factors influencing the natural history of colorectal liver metastases
  publication-title: Lancet
  doi: 10.1016/S0140-6736(94)92529-1
– volume: 4
  start-page: 1269
  year: 2014
  end-page: 1280
  ident: CR55
  article-title: Resistance to Anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-14-0462
– volume: 27
  start-page: 3677
  year: 2009
  end-page: 3683
  ident: CR4
  article-title: Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2008.20.5278
– volume: 18
  start-page: 1500
  year: 2020
  end-page: 1508
  ident: CR28
  article-title: A new surveillance algorithm after resection of colorectal liver metastases based on changes in recurrence risk and ras mutation status
  publication-title: J. Natl Compr. Cancer Netw. Jnccn.
  doi: 10.6004/jnccn.2020.7596
– volume: 233
  start-page: 272
  year: 2021
  end-page: 284.e13
  ident: CR29
  article-title: Genomic sequencing and insight into clinical heterogeneity and prognostic pathway genes in patients with metastatic colorectal cancer
  publication-title: J. Am. Coll. Surg.
  doi: 10.1016/j.jamcollsurg.2021.05.027
– volume: 381
  start-page: 1632
  year: 2019
  end-page: 1643
  ident: CR11
  article-title: Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1908075
– volume: 136
  start-page: 864
  year: 2001
  end-page: 869
  ident: CR52
  article-title: Safety and efficacy of radiofrequency thermal ablation in advanced liver tumors
  publication-title: Arch. Surg.
  doi: 10.1001/archsurg.136.8.864
– volume: 28
  start-page: 7698
  year: 2021
  end-page: 7706
  ident: CR60
  article-title: Failure to cure patients with colorectal liver metastases: the impact of the liver surgeon
  publication-title: Ann. Surg. Oncol.
  doi: 10.1245/s10434-021-10030-0
– volume: 27
  start-page: 1386
  year: 2016
  end-page: 1422
  ident: CR5
  article-title: ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
  publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. / ESMO
  doi: 10.1093/annonc/mdw235
– volume: 76
  start-page: 879
  year: 2021
  end-page: 888
  ident: CR54
  article-title: Advances in radiological staging of colorectal cancer
  publication-title: Clin. Radiol.
  doi: 10.1016/j.crad.2021.06.005
– volume: 16
  start-page: A50
  year: 2013
  ident: CR40
  article-title: Landmark analysis to adjust for immortal time bias in oncology studies using claims data linked to death data
  publication-title: Value Health
  doi: 10.1016/j.jval.2013.03.284
– volume: 26
  start-page: 791
  year: 2022
  end-page: 801
  ident: CR48
  article-title: Neither surgical margin status nor somatic mutation predicts local recurrence after R0-intent resection for colorectal liver metastases
  publication-title: J. Gastrointest. Surg.
  doi: 10.1007/s11605-021-05173-0
– ident: CR3
– volume: 372
  start-page: 2509
  year: 2015
  end-page: 2520
  ident: CR16
  article-title: PD-1 blockade in tumors with mismatch-repair deficiency
  publication-title: N. Engl. J. Med
  doi: 10.1056/NEJMoa1500596
– volume: 25
  start-page: 4575
  year: 2007
  end-page: 4580
  ident: CR21
  article-title: Actual 10-year survival after resection of colorectal liver metastases defines cure
  publication-title: J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.
  doi: 10.1200/JCO.2007.11.0833
– volume: 269
  start-page: 917
  year: 2019
  end-page: 923
  ident: CR47
  article-title: Deleterious effect of RAS and evolutionary high-risk TP53 double mutation in colorectal liver metastases
  publication-title: Ann. Surg.
  doi: 10.1097/SLA.0000000000002450
– volume: 16
  start-page: 735
  year: 2018
  end-page: 745
  ident: CR14
  article-title: Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives
  publication-title: Clin. Adv. Hematol. Oncol.
– volume: 235
  start-page: 759
  year: 2002
  end-page: 766
  ident: CR41
  article-title: Trends in long-term survival following liver resection for hepatic colorectal metastases
  publication-title: Ann. Surg.
  doi: 10.1097/00000658-200206000-00002
– volume: 239
  start-page: 818
  year: 2004
  end-page: 825
  ident: CR43
  article-title: Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases
  publication-title: Ann. Surg.
  doi: 10.1097/01.sla.0000128305.90650.71
– volume: 417
  start-page: 949
  year: 2002
  end-page: 954
  ident: CR6
  article-title: Mutations of the BRAF gene in human cancer
  publication-title: Nature
  doi: 10.1038/nature00766
– volume: 1
  start-page: 710
  year: 1983
  end-page: 719
  ident: CR62
  article-title: Analysis of survival by tumor response
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.1983.1.11.710
– volume: 41
  start-page: 729
  year: 2015
  end-page: 741
  ident: CR53
  article-title: Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus
  publication-title: Cancer Treat. Rev.
  doi: 10.1016/j.ctrv.2015.06.006
– volume: 167
  start-page: 103
  year: 2004
  end-page: 124
  ident: CR63
  article-title: The validation of surrogate end points by using data from randomized clinical trials: a case-study in advanced colorectal cancer
  publication-title: J. R. Stat. Soc. A.
  doi: 10.1111/j.1467-985X.2004.00293.x
– volume: 14
  start-page: 56
  year: 2012
  end-page: 61
  ident: CR24
  article-title: Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series
  publication-title: Colorectal Dis.
  doi: 10.1111/j.1463-1318.2010.02539.x
– volume: 36
  start-page: 773
  year: 2018
  end-page: 779
  ident: CR20
  article-title: Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2017.76.9901
– volume: 229
  start-page: 286
  year: 2019
  end-page: 294 e281
  ident: CR46
  article-title: Conditional recurrence-free survival after resection of colorectal liver metastases: persistent deleterious association with RAS and TP53 co-mutation
  publication-title: J. Am. Coll. Surg.
  doi: 10.1016/j.jamcollsurg.2019.04.027
– volume: 108
  start-page: 968
  year: 2021
  end-page: 975
  ident: CR49
  article-title: Contour prognostic model for predicting survival after resection of colorectal liver metastases: development and multicentre validation study using largest diameter and number of metastases with RAS mutation status
  publication-title: Br. J. Surg.
  doi: 10.1093/bjs/znab086
– volume: 1
  start-page: 710
  year: 1983
  ident: 353_CR62
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.1983.1.11.710
– volume: 27
  start-page: 3677
  year: 2009
  ident: 353_CR4
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2008.20.5278
– volume: 12
  start-page: 1571
  year: 2020
  ident: 353_CR8
  publication-title: Cancers
  doi: 10.3390/cancers12061571
– volume: 229
  start-page: 286
  year: 2019
  ident: 353_CR46
  publication-title: J. Am. Coll. Surg.
  doi: 10.1016/j.jamcollsurg.2019.04.027
– volume: 9
  start-page: 6256
  year: 2020
  ident: 353_CR61
  publication-title: Cancer. Med.
  doi: 10.1002/cam4.3316
– volume: 167
  start-page: 103
  year: 2004
  ident: 353_CR63
  publication-title: J. R. Stat. Soc. A.
  doi: 10.1111/j.1467-985X.2004.00293.x
– volume: 14
  start-page: 56
  year: 2012
  ident: 353_CR24
  publication-title: Colorectal Dis.
  doi: 10.1111/j.1463-1318.2010.02539.x
– volume: 233
  start-page: 272
  year: 2021
  ident: 353_CR29
  publication-title: J. Am. Coll. Surg.
  doi: 10.1016/j.jamcollsurg.2021.05.027
– ident: 353_CR39
– volume: 108
  start-page: 968
  year: 2021
  ident: 353_CR49
  publication-title: Br. J. Surg.
  doi: 10.1093/bjs/znab086
– volume: 239
  start-page: 818
  year: 2004
  ident: 353_CR43
  publication-title: Ann. Surg.
  doi: 10.1097/01.sla.0000128305.90650.71
– volume: 317
  start-page: 2392
  year: 2017
  ident: 353_CR38
  publication-title: JAMA
  doi: 10.1001/jama.2017.7105
– volume: 381
  start-page: 1632
  year: 2019
  ident: 353_CR11
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1908075
– volume: 224
  start-page: 509
  year: 1996
  ident: 353_CR33
  publication-title: Ann. Surg.
  doi: 10.1097/00000658-199610000-00009
– volume: 26
  start-page: 583
  year: 2022
  ident: 353_CR23
  publication-title: J. Gastrointest. Surg.
  doi: 10.1007/s11605-021-05110-1
– volume: 8
  start-page: 133
  year: 2021
  ident: 353_CR1
  publication-title: Genes Dis.
  doi: 10.1016/j.gendis.2019.10.013
– volume: 7
  start-page: 335
  year: 2006
  ident: 353_CR13
  publication-title: Nat. Rev. Mol. Cell Biol.
  doi: 10.1038/nrm1907
– volume: 18
  start-page: 1182
  year: 2017
  ident: 353_CR18
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(17)30422-9
– volume: 25
  start-page: 4575
  year: 2007
  ident: 353_CR21
  publication-title: J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.
  doi: 10.1200/JCO.2007.11.0833
– volume: 26
  start-page: 791
  year: 2022
  ident: 353_CR48
  publication-title: J. Gastrointest. Surg.
  doi: 10.1007/s11605-021-05173-0
– volume: 343
  start-page: 1405
  year: 1994
  ident: 353_CR35
  publication-title: Lancet
  doi: 10.1016/S0140-6736(94)92529-1
– volume: 372
  start-page: 2509
  year: 2015
  ident: 353_CR16
  publication-title: N. Engl. J. Med
  doi: 10.1056/NEJMoa1500596
– volume: 188
  start-page: 291
  year: 2018
  ident: 353_CR57
  publication-title: Am. J. Pathol.
  doi: 10.1016/j.ajpath.2017.07.023
– volume: 36
  start-page: 773
  year: 2018
  ident: 353_CR20
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2017.76.9901
– volume: 4
  start-page: 283
  year: 2012
  ident: 353_CR26
  publication-title: Clin. Epidemiol.
– volume: 53
  start-page: 780
  year: 1992
  ident: 353_CR59
  publication-title: Ann. Thorac. Surg.
  doi: 10.1016/0003-4975(92)91435-C
– volume: 96
  start-page: 261
  year: 2004
  ident: 353_CR65
  publication-title: JNCI: J. Natl. Cancer Inst.
  doi: 10.1093/jnci/djh034
– volume: 16
  start-page: 735
  year: 2018
  ident: 353_CR14
  publication-title: Clin. Adv. Hematol. Oncol.
– volume: 25
  start-page: 5843
  year: 2019
  ident: 353_CR30
  publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.
  doi: 10.1158/1078-0432.CCR-19-0863
– volume: 34
  start-page: 2311
  year: 1974
  ident: 353_CR12
  publication-title: Cancer. Res
– volume: 88
  start-page: 980
  year: 2001
  ident: 353_CR42
  publication-title: Br. J. Surg.
  doi: 10.1046/j.0007-1323.2001.01821.x
– volume: 357
  start-page: 409
  year: 2017
  ident: 353_CR17
  publication-title: Science
  doi: 10.1126/science.aan6733
– volume: 38
  start-page: 11
  year: 2020
  ident: 353_CR19
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.19.02107
– volume: 33
  start-page: 4023
  year: 2015
  ident: 353_CR9
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2015.63.2471
– volume: 136
  start-page: 864
  year: 2001
  ident: 353_CR52
  publication-title: Arch. Surg.
  doi: 10.1001/archsurg.136.8.864
– volume: 41
  start-page: 729
  year: 2015
  ident: 353_CR53
  publication-title: Cancer Treat. Rev.
  doi: 10.1016/j.ctrv.2015.06.006
– volume: 25
  start-page: 32
  year: 2011
  ident: 353_CR25
  publication-title: Oncol. (Williston Park)
– volume: 19
  start-page: 255
  year: 2017
  ident: 353_CR64
  publication-title: J. Mol. Diagn.
  doi: 10.1016/j.jmoldx.2016.09.011
– volume: 314
  start-page: 268
  year: 2006
  ident: 353_CR2
  publication-title: Science
  doi: 10.1126/science.1133427
– volume: 6
  start-page: 660
  year: 2015
  ident: 353_CR7
  publication-title: J. Gastrointest. Oncol.
– volume: 272
  start-page: 715
  year: 2020
  ident: 353_CR50
  publication-title: Ann. Surg.
  doi: 10.1097/SLA.0000000000004331
– volume: 20
  start-page: 985
  year: 2009
  ident: 353_CR36
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdn735
– volume: 239
  start-page: 818
  year: 2004
  ident: 353_CR22
  publication-title: Ann. Surg.
  doi: 10.1097/01.sla.0000128305.90650.71
– volume: 76
  start-page: 879
  year: 2021
  ident: 353_CR54
  publication-title: Clin. Radiol.
  doi: 10.1016/j.crad.2021.06.005
– volume: 55
  start-page: iii1
  year: 2006
  ident: 353_CR34
  publication-title: Gut
  doi: 10.1136/gut.2006.098053
– ident: 353_CR3
– volume: 4
  start-page: 1269
  year: 2014
  ident: 353_CR55
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-14-0462
– volume: 276
  start-page: 357
  year: 2022
  ident: 353_CR31
  publication-title: Ann. Surg.
  doi: 10.1097/SLA.0000000000004672
– volume: 22
  start-page: 3284
  year: 2004
  ident: 353_CR58
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2004.10.012
– volume: 383
  start-page: 2207
  year: 2020
  ident: 353_CR15
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2017699
– volume: 17
  start-page: 5
  year: 2006
  ident: 353_CR56
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdj007
– volume: 34
  start-page: S7
  year: 2007
  ident: 353_CR45
  publication-title: Semin Oncol.
  doi: 10.1053/j.seminoncol.2007.01.003
– volume: 27
  start-page: 1386
  year: 2016
  ident: 353_CR5
  publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. / ESMO
  doi: 10.1093/annonc/mdw235
– volume: 16
  start-page: A50
  year: 2013
  ident: 353_CR40
  publication-title: Value Health
  doi: 10.1016/j.jval.2013.03.284
– volume: 18
  start-page: 1500
  year: 2020
  ident: 353_CR28
  publication-title: J. Natl Compr. Cancer Netw. Jnccn.
  doi: 10.6004/jnccn.2020.7596
– volume: 241
  start-page: 715
  year: 2005
  ident: 353_CR44
  publication-title: Ann. Surg.
  doi: 10.1097/01.sla.0000160703.75808.7d
– volume: 235
  start-page: 759
  year: 2002
  ident: 353_CR41
  publication-title: Ann. Surg.
  doi: 10.1097/00000658-200206000-00002
– volume: 28
  start-page: 7698
  year: 2021
  ident: 353_CR60
  publication-title: Ann. Surg. Oncol.
  doi: 10.1245/s10434-021-10030-0
– volume: 16
  start-page: 1311
  year: 2005
  ident: 353_CR32
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdi246
– volume: 21
  start-page: 497
  year: 2020
  ident: 353_CR37
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(19)30862-9
– volume: 269
  start-page: 917
  year: 2019
  ident: 353_CR47
  publication-title: Ann. Surg.
  doi: 10.1097/SLA.0000000000002450
– volume: 15
  start-page: 91
  year: 2013
  ident: 353_CR27
  publication-title: HPB
  doi: 10.1111/j.1477-2574.2012.00557.x
– volume: 32
  start-page: 3515
  year: 2014
  ident: 353_CR10
  publication-title: J. Clin. Oncol.
  doi: 10.1200/jco.2014.32.15_suppl.3515
– volume: 14
  year: 2014
  ident: 353_CR51
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-14-810
– volume: 417
  start-page: 949
  year: 2002
  ident: 353_CR6
  publication-title: Nature
  doi: 10.1038/nature00766
SSID ssj0001851266
Score 2.5211456
Snippet Over the past two decades of successive clinical trials in metastatic colorectal cancer (CRC), the median overall survival of both control and experimental...
Abstract Over the past two decades of successive clinical trials in metastatic colorectal cancer (CRC), the median overall survival of both control and...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 16
SubjectTerms 692/4028/67/1059/99
692/4028/67/1504/1885
692/53/2422
692/699/1503/1504/1885
Antiviral drugs
Cancer Research
Chemotherapy
Colorectal cancer
Gene Therapy
Human Genetics
Immunotherapy
Inhibitor drugs
Internal Medicine
Medicine
Medicine & Public Health
Metastasis
Oncology
Targeted cancer therapy
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagXLigVrwCBRmJG1iNH7uOTxVFVBUSXGClvVm2Y8NKkG03WVX9951xvLtaHr3GTjQZz-PzjD1DyFt0K-AlNRPBJKbaNjEfzZRp57TkwiWR73F_-Tq9mKnP88m8BNz6cqxyYxOzoW6XAWPkJ0IDsgV3xvnp5RXDrlGYXS0tNO6TB1i6DKVaz_UuxgJwQkzH_nJADiDrebk3U8vmpAcsgvfLhGSYT5NM7fmmXML_X7jz7-OTf-RQs2s6PySPCqakH0YhOCL3YveYzL6twQqAHNFFjhvkMCAFiEpLKdWeYgyW_o6Dw1tFi0CxgDUaQHgnoDCsKJ7vpMM1zL6hN6AT_RMyO__0_eMFKz0UWAAsNjDjcUPmAdQF6drIfRRehjp5gHIx-Aj7sTRpHFc-ArKIYtLG6JJ0TVvDcGjlU3LQLbv4nNAGXBd3RnjeBmWcAaQLX9fOmMDrpHRF-IZ7NpQC49jn4pfNiW7Z2JHjFjhuM8etqsi77TuXY3mNO2ef4aJsZ2Jp7Pxgufphi6ZZ7U1SUvugJoCWuPSpVk7WImkAo7CBqsjxZklt0dfe7qSrIm-2w6BpmD5xXVyu8xzsGw-AsiLPRgnYUiLB53Nw7BXRe7KxR-r-SLf4mat5GwNWUwFZ7zdStCPr_6x4cfdfvCQPRRZswbg8JgfDah1fAXoa_OusIrcA4hZ8
  priority: 102
  providerName: ProQuest
– databaseName: Springer Nature HAS Fully OA
  dbid: AAJSJ
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3faxQxEB5qC-JLqVbtapUUfKvBzY9rNo9XsZSD9qUe9C0k2UQPdE_u9pD-905y2SunVfD1MjmG2ZnMl0zmC8C7lFYwSyrKvY5Utm2kLugzqqxVgnEbee7jvro-u5zKye3odgf40AuTL-1nSsu8TA-3wz4sETikZjAuaCp-CSofwV6iakff3huPJzeT-5MVBBGYdkqHTC2aByZvZaFM1v8QwvzzouRv1dKchC4OYL-gRzJe6_sUdkL3DB5flfr4IUxvVhj66Dxklg8L8tkfQVxKCn_qkqSDV_I99Da1Es08SazVadXDOT55wIKkS52k_4nSd-QOA2H5HKYXnz5_vKTl4QTqEYD1VLu0C3OI5LywbWAucCd8HR3it-BdwE1YHDWWSRcQTgQ-akOwUdimrXHYt-IF7HbzLhwBaTBfMau5Y62X2mqEt_jvymrtWR2lqoANhjS-sIqnxy2-mVzdFo1ZG9-g8U02vpEVnG7m_FhzavxT-jx9n41k4sPOP8wXX0zxD6OcjlIo5-UIIRITLtbSippHhQgUd00VHA9f15QgXRqucLOECImxCk42wxheqWZiuzBfZZn0WDyiyAperp1ho4nARM8wm1egttxkS9XtkW72NVN4a41LpUS13g8Oda_W303x6v_EX8MTnn2eUyaOYbdfrMIbhFC9e1ti5hf-zBa2
  priority: 102
  providerName: Springer Nature
Title Survival improvement for patients with metastatic colorectal cancer over twenty years
URI https://link.springer.com/article/10.1038/s41698-023-00353-4
https://www.ncbi.nlm.nih.gov/pubmed/36781990
https://www.proquest.com/docview/2775878211
https://www.proquest.com/docview/2776515392
https://pubmed.ncbi.nlm.nih.gov/PMC9925745
https://doaj.org/article/7b9f437bc4574113bf04a302f7650255
Volume 7
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LaxsxEB7S5NJLaWnabpoaFXJLRVYPW6ujYxKCoaEkNfgmJK1EDe0mxGtC_n1H2rUb93npaUGPZRjN6PukkUYARwlWECUV5V5HKus6Uhf0iCprlWDcRp7vcX-8HF3M5HQ-nD966iudCevSA3eKO1FORymU83KI4MeEi6W0ouRRIbdAPpxmX8S8R4upvLuCRAKhp78lU4rqZInMI90m44Km6JmgcguJcsL-37HMXw9L_hQxzUB0_hye9QySjDvJX8BOaF7C7HqFPo9WQxZ5lyBv-hEkpKRPnLokaceVfAutTXeIFp6kdNVpusM-Pg39HUmnOUl7j60fyAN6wHIfZudnnycXtH8xgXpkXi3VLi2_HFI4L2wdmAvcCV9Gh8QteBdw9RWHlWXSBeQRgQ_rEGwUtqpLrPa1eAW7zU0T3gCpEKiY1dyx2kttNfJa_LuyWntWRqkKYGvtGd-nE0-vWnw1OawtKtNp3KDGTda4kQUcb_rcdsk0_tr6NA3KpmVKhJ0L0DxMbx7mX-ZRwOF6SE3vnUvDFa6SkBoxVsD7TTX6VQqW2CbcrHKb9Eo80scCXncWsJFEIMIzhPEC1JZtbIm6XdMsvuTc3VrjHClRrA9rK_oh1p9VcfA_VPEWnvJs_pwycQi77d0qvENG1boBPFFzNYC98Xh6PcXv6dnlpyssnYwmg-xY3wFniSBQ
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKOcAFgXiFFjASnMBq_Nh1fECIV7WljwtdaW_GduyyEs2WTVbV_il-I2Mn2dXy6K3X2Imc8XjmmxnPDEIvo1oBLSkJcyoQUZaBWK-GRBojOWUmsJTHfXwyHI3Fl8lgsoV-9bkw8VplLxOToC5nLvrI95gEZAvqjNJ3Fz9J7BoVo6t9C42WLQ798hJMtvrtwSfY31eM7X8-_TgiXVcB4gCdNETZaKJYgDmOm9JT65nlLg8WwI131oOFEgaFocJ60LWeDUrvTeCmKHMYdiWH795AN0Hx5tHYkxO59ukAfGHDtp8d_D4g-UmXp5PzYq8G7BPz2RgnMX7HidjQhallwL9w7t_XNf-I2SZVuH8X3ekwLH7fMt09tOWr-2j8dQFSB_gWT5OfIrkdMUBi3JVurXH0-eJz35iYxTR1OBbMjgIX3nGR-eY43ifFzSXMXuIlELt-gMbXQt2HaLuaVf4xwgWoSmoUs7R0QhkFyBq-Lo1SjuZByAzRnnradQXNY1-NHzoF1nmhW4proLhOFNciQ69X71y05TyunP0hbspqZizFnR7M5me6O9laWhUEl9aJAaAzym3IheE5CxLALxhsGdrtt1R38qHWa27O0IvVMJzsGK4xlZ8t0pzYpx4AbIYetRywWgkHjEEBSGRIbvDGxlI3R6rp91Q9XCmQ0gKW9abnovWy_k-KJ1f_xXN0a3R6fKSPDk4Od9BtlpicEcp30XYzX_ingNwa-ywdF4y-Xff5_A08clYr
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LbxMxEB6VVKq4IN4sFDASNzCsH4nXx_CISqAVUonUm2V7bYgEmyrZCPXfM3Z2UwUKEtf1eDUaz3g-ex4GeJ7cCnpJRbnXkcq6jtQFPaLKWiUYt5HnOu7jk9HRTE7Phmd7MOprYXLSfm5pmbfpPjvs9QqBQyoG44Km4Jeg8tV5Ha_BPuJtJgewPx5PT6eXtysIJND1dFUypaiu-MGOJ8oN-69CmX8mS_4WMc2OaHITbnQIkow3PN-CvdDchoPjLkZ-B2anazR_VCAyzxcG-f6PIDYlXQ_VFUmXr-RHaG0qJ5p7kjpXp50P5_ikBUuSEjtJ-xOpL8gFGsPqLswm77-8PaLd4wnUIwhrqXbpJOYQzXlh68Bc4E74MjrEcMG7gAexOKwsky4gpAh8WIdgo7BVXeKwr8U9GDSLJjwAUqHPYlZzx2ovtdUIcfHvymrtWRmlKoD1gjS-6yyeHrj4bnKEW1RmI3yDwjdZ-EYW8GI753zTV-Of1G_S-mwpU0_s_GGx_Go6HTHK6SiFcl4OESYx4WIprSh5VIhC8eRUwGG_uqYz1JXhCg9MiJIYK-DZdhhNLMVNbBMW60yTHoxHJFnA_Y0ybDkR6OwZevQC1I6a7LC6O9LMv-U23lrjdimRrZe9Ql2y9XdRPPw_8qdw8PndxHz6cPLxEVznWf05ZeIQBu1yHR4jomrdk858fgEzxBqu
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Survival+improvement+for+patients+with+metastatic+colorectal+cancer+over+twenty+years&rft.jtitle=NPJ+precision+oncology&rft.au=Fadl+A.+Zeineddine&rft.au=Mohammad+A.+Zeineddine&rft.au=Abdelrahman+Yousef&rft.au=Yue+Gu&rft.date=2023-02-13&rft.pub=Nature+Portfolio&rft.eissn=2397-768X&rft.volume=7&rft.issue=1&rft.spage=1&rft.epage=9&rft_id=info:doi/10.1038%2Fs41698-023-00353-4&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_7b9f437bc4574113bf04a302f7650255
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2397-768X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2397-768X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2397-768X&client=summon